Condition
High Bleeding Risk clinical trials and research
As of November 12, 2026, Find a Trial lists 2 High Bleeding Risk clinical trials that are recruiting, at sites in 2 countries (most in Japan (1), Italy (1)). By phase: Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
No blood-thinners versus aspirin after left atrial appendage closure
This trial tests whether skipping antithrombotic drugs after left atrial appendage closure (using only 45 days of oral anticoagulant) is as safe and effective as taking aspirin for people with nonvalvular atrial fibrillation who are at high bleeding risk.
-
Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients
This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.
Related topics
Quick answers
How many High Bleeding Risk clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in Japan (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.